Loading clinical trials...
Loading clinical trials...
This phase II trial studies the side effects and how well daratumumab works in treating patients with multiple myeloma when the infusion is accelerated. Monoclonal antibodies, such as daratumumab, may...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Ohio State University Comprehensive Cancer Center
NCT06356571 · Plasma Cell Myeloma Refractory
NCT05334069 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and more
NCT05312255 · Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, and more
NCT04508790 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
NCT03141437 · Breast Neoplasm, Colorectal Neoplasm, and more
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions